ClinicalTrials.gg
Drug

Pasireotide clinical trials

Also written SOM230.

Includes 2 studies of Pasireotide diaspartate.

studies test it
59
open now
2
in phase 3
7
first study started
2004

How each study uses pasireotide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pasireotide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Dec 2012 · SIGNIFOR · NDA 200677 (FDA, Drugs@FDA; as pasireotide diaspartate)
European Union
24 Apr 2012 · Signifor · EMEA/H/C/002052 (EMA; as pasireotide diaspartate)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pasireotide
31
Pasireotide LAR
13
Signifor
4
Pasireotide s.c.
3
SOM 230 / Pasireotide
2

Development codes

SOM230
30

Studies by the year they started

59 studies that test it; most in 2011 (8)

Studies that test pasireotide, by start year
YearStudies
20045
20062
20071
20086
20094
20105
20118
20126
20135
20142
20153
20163
20173
20181
20191
20201
20243

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
38
Phase 3
7
Phase 4
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 26 · Other 33

Novartis Pharmaceuticals (23) · RECORDATI GROUP (2) · Emory University (2) · NYU Langone Health (2) · Memorial Sloan Kettering Cancer Center (2) · Hospices Civils de Lyon (1) · Nxera Pharma UK Limited (1) · Anthony Sung, MD (1)

Often tested with

Tested in the same studies.

Everolimus (3) · Cabergoline (2) · HTL0030310 (1) · Insulin (1) · Octreotide (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test pasireotide.

Studies

Open first, then newest update. How each study uses pasireotide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 59

See all 59 studies that test pasireotide →

Given beside what is tested · 5 — pasireotide is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with pasireotide

Codes

What other systems call pasireotide · ClinicalTrials.gg INT005042

  • MeSH (NLM) C517782pasireotideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 98H1T17066PASIREOTIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 1364105Confirmed FDA, Wikidata
  • Wikidata Q3896970pasireotideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C69131PasireotideConfirmed FDA, Wikidata
  • DrugBank DB06663One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.